Atopica for cats (cyclosporine oral solution, USP) is indicated for the control of feline allergic dermatitis as manifested by excoriations (including face and neck), miliary dermatitis, eosinophilic plaques, and self-induced alopecia in cats at least 6 months of age and 1.4kg body weight.
Cats with no previous exposure to Toxoplasma gondii may be at risk of developing clinical toxoplasmosis if they become infected while under treatment with Atopica for Cats. In cases of clinical toxoplasmosis or other serious systemic illness, stop treatment with cyclosporine and initiate appropriate therapy.
Cats can be tested for previous toxoplasmosis exposure by measurement of IgG and IgM. However, interpretation of titers can be complicated as there are no agreed titer levels above which previous exposure and immunity can be confirmed; veterinarians should consult with their laboratory.Pet owners should be advised to minimize potential exposure of seronegative cats to Toxoplasma. Explain that they should:
Treatment with Atopica for Cats has been shown not to increase Toxoplasma oocyst shedding, a potential source of zoonotic disease.
As with Atopica for Dogs, there is no need to monitor cyclosporine blood levels during administration of Atopica for Cats as no correlation has been shown between blood levels and efficacy or safety.
References: 1. Steffan J et al. Vet Dermatol (2013);24:315-e70. 2. King S et al. Vet Dermatol (2012);23:440-e84. 3. Roberts ES et al. J Feline Med Surg (2016);1-9.